S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
NASDAQ:NMTR

9 Meters Biopharma Stock Forecast, Price & News

$1.32
0.00 (0.00 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$1.24
Now: $1.32
$1.32
50-Day Range
$0.72
MA: $0.99
$1.42
52-Week Range
$0.44
Now: $1.32
$1.77
Volume145,531 shs
Average Volume23.97 million shs
Market Capitalization$198.43 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.

MarketRank

Overall MarketRank

1.38 out of 5 stars

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NMTR
CUSIPN/A
CIKN/A
Phone919-275-1933
Employees8

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.27) per share

Profitability

Net Income$-27,050,000.00

Miscellaneous

Market Cap$198.43 million
Next Earnings Date2/8/2021 (Estimated)
OptionableOptionable
$1.32
0.00 (0.00 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NMTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











9 Meters Biopharma (NASDAQ:NMTR) Frequently Asked Questions

Is 9 Meters Biopharma a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 9 Meters Biopharma stock.
View analyst ratings for 9 Meters Biopharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than 9 Meters Biopharma?

Wall Street analysts have given 9 Meters Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 9 Meters Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is 9 Meters Biopharma's next earnings date?

9 Meters Biopharma is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for 9 Meters Biopharma
.

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) posted its earnings results on Saturday, November, 14th. The company reported ($0.06) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.06).
View 9 Meters Biopharma's earnings history
.

What price target have analysts set for NMTR?

5 brokers have issued 12-month price objectives for 9 Meters Biopharma's shares. Their forecasts range from $5.00 to $5.00. On average, they expect 9 Meters Biopharma's stock price to reach $5.00 in the next year. This suggests a possible upside of 278.8% from the stock's current price.
View analysts' price targets for 9 Meters Biopharma
or view Wall Street analyst' top-rated stocks.

Who are some of 9 Meters Biopharma's key competitors?

What other stocks do shareholders of 9 Meters Biopharma own?

Who are 9 Meters Biopharma's key executives?

9 Meters Biopharma's management team includes the following people:
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 65, Pay $513.12k)
  • Mr. John Temperato, Pres, CEO & Director (Age 55)
  • Mr. Edward J. Sitar CPA, CPA, Chief Financial Officer (Age 57)
  • Mr. Sireesh Appajosyula Pharm.D., Sr. VP of Corp. Devel. & Operations
  • Jerry Gardner, Head of Clinical Strategy
  • Dr. Nir Barak, Sr. VP of Scientific Affairs
  • Dr. Peter H. R. Green M.D., Clinical & Scientific Advisor and Consultant
  • Mr. Joseph A. Murray, Clinical & Scientific Advisor and Consultant
  • Dr. Ciaran P. Kelly M.D., Clinical & Scientific Advisor and Consultant
  • Dr. Elena Verdu M.D., Ph.D., Clinical & Scientific Advisor and Consultant

What is 9 Meters Biopharma's stock symbol?

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 9 Meters Biopharma's stock price today?

One share of NMTR stock can currently be purchased for approximately $1.32.

How big of a company is 9 Meters Biopharma?

9 Meters Biopharma has a market capitalization of $198.43 million. 9 Meters Biopharma employs 8 workers across the globe.

What is 9 Meters Biopharma's official website?

The official website for 9 Meters Biopharma is www.9meters.com.

How can I contact 9 Meters Biopharma?

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.